| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue | $670.1M+10.4% | $607.2M+19.8% | $506.9M+8075.8% | $6.2M-16.2% | $7.4M |
| Total cost of revenue | $372.3M+5.6% | $352.4M+23.2% | $286.0M+142900.0% | $200K-75.0% | $800K |
| Gross profit | $1.58B-4.4% | $1.65B+9.0% | $1.51B+15.9% | $1.31B+7.9% | $1.21B |
| Selling, general and administrative | $946.5M+5.9% | $893.8M+22.5% | $729.4M+20.1% | $607.4M+8.2% | $561.2M |
| Research and development | $395.2M+5.0% | $376.5M+27.7% | $294.8M+25.0% | $235.9M+6.8% | $220.8M |
| Goodwill impairment charge | $96.5M | $0 | $0 | — | — |
| Other charges, net | $71.3M-43.5% | $126.1M+141.6% | $52.2M+75.8% | $29.7M+107.7% | $14.3M |
| Total operating expenses | $1.51B+8.1% | $1.40B+29.7% | $1.08B+23.3% | $873.0M+9.6% | $796.3M |
| Operating income | $68.2M-73.1% | $253.1M-42.1% | $436.9M+1.0% | $432.7M+4.7% | $413.3M |
| Bargain purchase gain and associated measurement period adjustments | $0+100.0% | -$8.0M-105.6% | $144.1M | $0 | — |
| Interest and other expense, net | -$46.2M-20.9% | -$38.2M-3.8% | -$36.8M-95.7% | -$18.8M+4.6% | -$19.7M |
| Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | $22.0M-89.4% | $206.9M-62.0% | $544.2M+31.5% | $413.9M+5.2% | $393.6M |
| Income tax provision | $29.3M-67.9% | $91.4M-22.3% | $117.7M+1.1% | $116.4M+3.0% | $113.0M |
| Equity in (losses) income of unconsolidated investees, net of tax | -$1.0M+41.2% | -$1.7M-185.0% | $2.0M+100.0% | $1.0M | — |
| Consolidated net (loss) income | -$8.3M-107.3% | $113.8M-73.4% | $428.5M+43.6% | $298.5M+6.4% | $280.6M |
| Net income attributable to noncontrolling interests in consolidated subsidiaries | $300K-57.1% | $700K-46.2% | $1.3M-31.6% | $1.9M-45.7% | $3.5M |
| Net (loss) income attributable to Bruker Corporation | -$8.6M-107.6% | $113.1M-73.5% | $427.2M+44.0% | $296.6M+7.0% | $277.1M |
| Dividends on Series A Mandatory Convertible Preferred Stock | $13.9M | $0 | $0 | — | — |
| Net (loss) income attributable to Bruker Corporation common shareholders | -$22.5M-119.9% | $113.1M-73.5% | $427.2M | — | — |
| Basic | $151.8M+1.9% | $149.0M+1.8% | $146.4M-1.5% | $148.6M-1.8% | $151.4M |
| Diluted | $151.8M+1.5% | $149.5M+1.6% | $147.2M-1.5% | $149.4M-2.3% | $152.9M |
| Product revenue | |||||
| Service and other revenue | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.